These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 38760825)

  • 21. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis.
    Amjad W; Jiang ZG; Lai M
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1038-1045. PubMed ID: 38829950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score.
    Peng L; Li L; Liu J; Li Y
    Front Nutr; 2023; 10():1320238. PubMed ID: 38249604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
    Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
    Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver disease.
    Cheng WC; Wong PY; Wu CD; Cheng PN; Lee PC; Li CY
    Environ Health Prev Med; 2024; 29():7. PubMed ID: 38346730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study.
    Bao X; Kang L; Yin S; Engström G; Wang L; Xu W; Xu B; Zhang X; Zhang X
    Alzheimers Res Ther; 2024 Jun; 16(1):136. PubMed ID: 38926784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease.
    Yin Y; Zhu W; Xu Q
    Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1922-1931. PubMed ID: 38866613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.
    Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U
    Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the clinical value of five noninvasive predictors of metabolic dysfunction-associated steatotic liver disease in Han Chinese adults.
    Ma X; Zou H; Zhan J; Gao J; Xie Y
    Eur J Gastroenterol Hepatol; 2024 Oct; 36(10):1209-1219. PubMed ID: 38973526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overall and Sex-Specific Associations of Serum Lipid-Soluble Micronutrients with Metabolic Dysfunction-Associated Steatotic Liver Disease among Adults in the United States.
    Chai W; Tao MH
    Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between serum ferritin and non-alcoholic fatty liver disease among middle-aged and elderly Chinese with normal weight.
    You G; Ding J; Shen J; Wang Y; Sun Y
    Asia Pac J Clin Nutr; 2019; 28(4):747-753. PubMed ID: 31826372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
    Lv Q; Zhao H
    Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
    [No Abstract]   [Full Text] [Related]  

  • 37. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
    Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.